公开(公告)号：WO9806823A3

公开(公告)日：1998-05-07

申请号：PCT/US9713759

申请日：1997-08-13

Applicant: BAXTER INT

Inventor： VACHULA MONA ,  VAN EPPS DENNIS E ,  ALZONA MORTIMER T ,  AONO FREDERICK M

IPC: A61K38/00 ,  C12N5/0783 ,  C12N5/0784 ,  C12N5/06

CPC classification number: C12N5/0636 ,  A61K38/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N5/0639 ,  C12N2500/05 ,  C12N2500/14 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2501/01 ,  C12N2501/02 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/25 ,  C12N2501/515

Abstract: A method for producing human dendritic cells for therapeutic purposes which allows culture-deriving dendritic cells using no cytokines, or reduced cytokines. The method involves culturing mononuclear cells from blood or bone marrow in a medium containing at least one agent such as a calcium ionophore, e.g. A23187, theophylline, protaglandin E1, dibutyryl cyclic AMP, Vitamin D3, Vitamin E, retinoic acid, or a fatty acid. The culture is maintained for a sufficient time, typically 4 - 14 days, to produce a culture enriched for dendritic cells, as evidenced by at least about 2.5 % of total cells exhibiting dendritic cell processes, or a dendritic cell antigen such as CD80, CD86, or CD1a. Also provided is a method to produce antigen-specific human T-cells by pulsing the dendritic cells obtained by the method of the invention with an antigen such as a viral, tumor, bacterial, or cell surface antigen, and then co-culturing T-cells with the antigen-pulsed dendritic cells. Useful for treatment of viral or bacterial infections, useful as a cancer vaccine, useful to induce tolerance of allo- or xeno-graft.

Abstract translation: 用于制备用于治疗目的的人树突状细胞的方法，其允许不使用细胞因子的培养物衍生的树突状细胞或减少的细胞因子。 该方法包括在含有至少一种如钙离子载体的试剂的培养基中从血液或骨髓中培养单核细胞。 A23187，茶碱，protaglandin E1，二丁酰环AMP，维生素D3，维生素E，视黄酸或脂肪酸。 培养物保持足够的时间，通常为4-14天，以产生富含树突状细胞的培养物，如通过表达树突状细胞过程的总细胞的至少约2.5％或树突状细胞抗原如CD80，CD86所证明的 ，或CD1a。 还提供了通过用抗原如病毒，细胞或细胞表面抗原脉冲通过本发明的方法获得的树突细胞产生抗原特异性人T细胞的方法，然后共培养T- 细胞与抗原脉冲的树突状细胞。 可用于治疗病毒或细菌感染，可用作癌症疫苗，可用于诱导同种异体或异种移植物的耐受性。

公开(公告)号：EP0590132A4

公开(公告)日：1996-01-31

申请号：EP93908609

申请日：1993-03-23

Applicant: BAXTER INT

Inventor： BENDER JAMES G ,  MAPLES PHILLIP B ,  SMITH STEPHEN ,  UNVERZAGT KRISTEN L ,  VAN EPPS DENNIS E

IPC: A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K48/00 ,  A61P7/00 ,  C12N5/0787 ,  A01N1/00 ,  C12N5/00 ,  C12N5/06 ,  C12N5/08

CPC classification number: A61K35/15 ,  A61K48/00 ,  A61K2039/5156 ,  C12N5/0642 ,  C12N2500/44 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/39

Abstract: The present invention provides a composition of human neutrophil precursor cells having at least 37% myeloblasts and promyeloblasts. Also provided are hematopoietic cell suspensions that have human neutrophil precursor cells and at least one hematopoietic growth factor.

Abstract translation: 本发明提供了具有至少37％的成髓细胞和前胚细胞的人嗜中性粒细胞前体细胞的组合物。 还提供了具有人嗜中性粒细胞前体细胞和至少一种造血生长因子的造血细胞悬浮液。

公开(公告)号：DE60132221D1

公开(公告)日：2008-02-14

申请号：DE60132221

申请日：2001-05-23

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： SCHAEFFER ANDREW T ,  TSENG-LAW JANET ,  THORNTON JEFFREY R ,  VAN EPPS DENNIS E

IPC: C07K7/06 ,  G01N33/53 ,  A61K35/12 ,  A61K47/48 ,  A61P35/00 ,  A61P37/04 ,  A61P37/06 ,  C07K1/04 ,  C07K7/08 ,  C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  C12N5/06 ,  C12N5/08 ,  C12Q1/02 ,  G01N33/543 ,  G01N33/569 ,  G01N33/574

Abstract: The present invention provides peptide-ligand conjugates containing a peptide, where a free form of the peptide is capable of displacing a second ligand specific for the peptide. The invention also provides a method of selecting a cell. The method includes the steps of contacting a cell population with a peptide-ligand conjugate, wherein the conjugate comprises a first ligand specific for a cell in the population conjugated to a peptide capable of displacing a second ligand specific for the peptide, thereby forming a cell-conjugate complex; contacting the peptide-ligand conjugate with the second ligand; and isolating the cell-conjugate complex. The method can further include the step of adding a free form of the peptide to release the cell from the complex. The invention also provides a subpopulation of cells containing two or more specifically isolated cells and methods of isolating cell subpopulations. The invention additionally provides a method of diagnosing a condition using peptide-ligand conjugates. The invention further provides a kit for isolating a cell containing a peptide capable of displacing an antibody specific for the peptide and the antibody.

公开(公告)号：DE60132221T2

公开(公告)日：2009-01-02

申请号：DE60132221

申请日：2001-05-23

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： SCHAEFFER ANDREW T ,  TSENG-LAW JANET ,  THORNTON JEFFREY R ,  VAN EPPS DENNIS E

IPC: C07K7/06 ,  G01N33/53 ,  A61K35/12 ,  A61K47/48 ,  A61P35/00 ,  A61P37/04 ,  A61P37/06 ,  C07K1/04 ,  C07K7/08 ,  C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  C12N5/06 ,  C12N5/08 ,  C12Q1/02 ,  G01N33/543 ,  G01N33/569 ,  G01N33/574

Abstract: The present invention provides peptide-ligand conjugates containing a peptide, where a free form of the peptide is capable of displacing a second ligand specific for the peptide. The invention also provides a method of selecting a cell. The method includes the steps of contacting a cell population with a peptide-ligand conjugate, wherein the conjugate comprises a first ligand specific for a cell in the population conjugated to a peptide capable of displacing a second ligand specific for the peptide, thereby forming a cell-conjugate complex; contacting the peptide-ligand conjugate with the second ligand; and isolating the cell-conjugate complex. The method can further include the step of adding a free form of the peptide to release the cell from the complex. The invention also provides a subpopulation of cells containing two or more specifically isolated cells and methods of isolating cell subpopulations. The invention additionally provides a method of diagnosing a condition using peptide-ligand conjugates. The invention further provides a kit for isolating a cell containing a peptide capable of displacing an antibody specific for the peptide and the antibody.

公开(公告)号：CA2109729A1

公开(公告)日：1993-09-30

申请号：CA2109729

申请日：1993-03-23

Applicant: BAXTER INT

Inventor： BENDER JAMES G ,  MAPLES PHILLIP B ,  SMITH STEPHEN ,  UNVERZAGT KRISTEN L ,  VAN EPPS DENNIS E

IPC: A61K35/12 ,  A61K35/14 ,  A61K35/15 ,  A61K35/28 ,  A61K39/00 ,  A61K48/00 ,  A61P7/00 ,  C12N5/0787 ,  C12N5/08

Abstract: 2109729 9318648 PCTABS00025 A composition comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16 % human myeloblasts and promyelocytes, which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5 % colony forming units (CFU) of at least about 50 cells is provided. An alternative composition comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16 % CD15+CD11b cells and less than about 5 % colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60 % of the CD15+CD11b- cells are myeloblasts and promyelocytes.

公开(公告)号：CA2168091A1

公开(公告)日：1995-03-02

申请号：CA2168091

申请日：1994-08-23

Applicant: BAXTER INT

Inventor： SMITH STEPHEN L ,  QIAO XIAOYING ,  MACIUKAS SUSAN M ,  BENDER JAMES G ,  VAN EPPS DENNIS E ,  LOUDOVARIS MAUREEN F

IPC: C12Q1/06 ,  A61K35/12 ,  A61K35/14 ,  C12N5/078 ,  C12N5/0787 ,  C12N5/08 ,  C12N5/02

Abstract: The invention provides serum-free, animal protein-free media formulations to be used in conjunction with hematopoietic growth factors for the in vitro growth of human neutrophil and megakaryocyte precursors. The medium is comprised of a base medium, corticosteriod, transferrin, insulin, cholesterol, ethanolamine, and human albumin. The invention also provides methods for preparing serum-free, animal protein-free suspensions of human hematopoietic precursor cells wherein the cellular component comprises at least about 16 % neutrophil precursors and at least about 1 % megakaryocyte precursors. Serum-free, animal protein-free suspensions of human hematopoietic cells are provided wherein the cellular component comprises at least about 30 %, preferably greater than 60 % neutrophil precursors. The neutrophil precursors are comprised of blast cells, promyelocytes, neutrophilic myelocytes, and neutrophilic metamyelocytes. Also provided are serum-free, animal protein-free cell suspensions wherein the cellular component comprises at least about 3 %, preferably greater than 8 % megakaryocyte precursors. Also provided are serum-free, animal-protein free cell suspensions wherein the cellular component comprises colony-forming units and cluster-forming units.

公开(公告)号：CA2160871A1

公开(公告)日：1994-11-10

申请号：CA2160871

申请日：1994-04-14

Applicant: BAXTER INT

Inventor： BENDER JAMES G ,  VAN EPPS DENNIS E ,  UNVERZAGT KRISTEN

IPC: A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K35/407 ,  A61K35/54 ,  A61P7/06 ,  C12N5/078 ,  C12N5/08 ,  C12Q1/02

Abstract: The invention provides a method of preparing from hematopoietic cells a population of cells enriched for erythroid progenitor cells (BFU-E) in which up to 100% of the colony-forming units are BFU-E. The method entails separating hematopoietic progenitor cells on the basis of binding to a specific cell surface antigen such as CD34, and separation of erythroid progenitor cells based on binding to a lectin such as Ulex europaeus agglutinin. After separation of the erythroid progenitors, the lectin may be eluted off the cells by incubation with excess sugar, such as fucose, which competes for the cell-binding site on the lectin. The invention also provides a method of treatment for human patients having an erythroid disorder via administration of a cell population enriched for human erythroid progenitor cells. Also provided are diagnostic methods based on the enriched cell population.